Spyre Therapeutics (SYRE) Prepaid Assets (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Prepaid Assets came in at $22.5 million in Q1 2026, up 354.45% YoY from $4.9 million in Q1 2025, and up 5.83% on a QoQ basis from $21.2 million in Q4 2025.
Analysis
Spyre Therapeutics (SYRE) Prepaid Assets (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Prepaid Assets data on file, last reported at $22.5 million in Q1 2026.
- Quarterly Prepaid Assets rose 354.45% year-over-year to $22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.5 million (up 354.45% YoY) and the FY2025 annual result came in at $21.2 million, up 294.5% from the prior year.
- Prepaid Assets improved to $22.5 million in Q1 2026, from $21.2 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $22.5 million in Q1 2026 to a low of $2.2 million in Q3 2023.
- A 5-year average of $8.4 million and a median of $6.2 million in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets plunged 72.23% — and 2026, when it soared 354.45%.
- Tracing SYRE's Prepaid Assets over 5 years: stood at $6.2 million in 2022, then slumped by 63.53% to $2.3 million in 2023, then jumped by 139.27% to $5.4 million in 2024, then surged by 294.5% to $21.2 million in 2025, then grew by 5.83% to $22.5 million in 2026.
- The last three Prepaid Assets figures came in at $22.5 million (Q1 2026), $21.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 7.53 Bn | 7.53 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.66 Mn |
| Mar 31, 2026 | 22.49 Mn |
| Dec 31, 2025 | 21.25 Mn |
| Sep 30, 2025 | 18.41 Mn |
| Jun 30, 2025 | 12.25 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 6.85 Mn |
| Jun 30, 2024 | 9.74 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.19 Mn |
| Jun 30, 2023 | 2.88 Mn |
| Mar 31, 2023 | 5.57 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.87 Mn |
| Jun 30, 2022 | 7.62 Mn |
| Mar 31, 2022 | 4.86 Mn |
| Dec 31, 2021 | 4.95 Mn |
| Sep 30, 2021 | 5.09 Mn |